EN DE
Watch Shanghai Bio-heart Biological for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shanghai Bio-heart Biological (2185) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Shanghai Bio-heart Biological stock HK$0.93, price HK$0.90, upside +3.0%, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

SB Shanghai Bio-heart Biological logo Thin data Nov 10, 2026

Shanghai Bio-heart Biological

2185 · HK

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value HK$0.9274 · Fairly valued 
Quality 43/100 
Revenue last quarter 31% below a year ago. 
Falling price (downtrend) 
Weak Growth 
Loss-making · -196.4% net margin (TTM) 
Negative free cash flow 
Trails peers (2/8) 
Narrow moat 12/100
Thin data 
Estimate
Watch Shanghai Bio-heart Biological for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$2,939 HK$0.9000 Fair Value HK$0.9274 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.9000 – HK$2,939 · fair‑value band HK$0.6956 – HK$1.16 · the HK$0.9000 price screens below the HK$0.9274 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Shanghai Bio-heart Biological in your weekly email

Every Wednesday you see whether Shanghai Bio-heart Biological is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China.

Show moreShow less

The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis.

It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.

Stock analysis

Shanghai Bio-heart Biological (2185) currently trades at HK$0.9000, while our estimate is HK$0.9274, so the stock looks roughly fairly valued today (gap 2.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.6956 (bear) to HK$1.16 (bull), the price of HK$0.9000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Shanghai Bio-heart Biological reported revenue of 43.8M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −68.2M CNY in FY2025.

Key figures

Market cap HK$222M (≈ $28.4M) Micro · P/S ratio 6.27 · Return on equity −12.2% · Return on assets (EBIT) −20.7% (5-year average) · Operating margin −261% · Revenue (TTM) 38.4M CNY · Revenue growth (YoY) −31.1% · Free cash flow −72.9M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 88% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 3%, 2185 screens richer than that median.

Fair Value

Bear HK$0.6956 Fair Value HK$0.9274 Bull HK$1.16
Price HK$0.9000 · Upside +3.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2185, get fair value alerts →

Compare Shanghai Bio-heart Biological with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside +3.0% · Above median
Profitability
Return on assets −8.2% · Below median
Net margin (12 months) −196.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −31.1% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.43× · Cheapest 25%
P/S (12 months) 4.92× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 16
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Boston Scientific Corporation BSX $44.34 $49.64 +12% vs 2185
Stryker Corporation SYK $309.64 $343.63 +11% vs 2185
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 2185
STERIS plc STE $264.32 $281.90 +7% vs 2185
DexCom, Inc DXCM $83.33 $88.38 +6% vs 2185
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 2185
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 2185
Medtronic plc MDT $102.86 $74.90 −27% vs 2185
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 2185
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 2185

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Bio-heart Biological: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shanghai Bio-heart Biological Fair Value". https://www.fairvalue-calculator.com/stock/2185

Frequently asked questions

Is Shanghai Bio-heart Biological (2185) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.9274 versus a price of HK$0.9000, about +3% upside (fairly valued).
What is the fair value of 2185?
Our estimate for Shanghai Bio-heart Biological is HK$0.9274 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.9000.
What is the quality score of 2185?
Shanghai Bio-heart Biological has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Bio-heart Biological (2185)?
Our calculated price target is the estimate of HK$0.9274 (as of Nov 10, 2026). Cautious scenario HK$0.6956, optimistic scenario HK$1.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Shanghai Bio-heart Biological stock forecast for 2026?
Our estimate puts fair value at HK$0.9274, about +3% upside versus a price of HK$0.9000 (fairly valued). Cautious scenario HK$0.6956, optimistic scenario HK$1.16. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Bio-heart Biological (2185)?
Shanghai Bio-heart Biological reported trailing-twelve-month revenue of about 38.4M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Shanghai Bio-heart Biological (2185)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Bio-heart Biological it is HK$0.9274 per share (as of Nov 10, 2026), against a price of HK$0.9000.
Is Shanghai Bio-heart Biological stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2185 trades below its calculated fair value: price HK$0.9000, fair value HK$0.9274, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2185?
No. The price is what the market pays today (HK$0.9000); the fair value is what the company's own numbers justify (HK$0.9274). For Shanghai Bio-heart Biological the two are HK$0.0274 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Bio-heart Biological worth?
The market values Shanghai Bio-heart Biological at about HK$222M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.9000; our models calculate a fair value of HK$0.9274 per share.
What do the bullish and bearish scenarios say about 2185?
Our models span a range for Shanghai Bio-heart Biological: cautious scenario HK$0.6956, base HK$0.9274, optimistic HK$1.16 per share (as of Nov 10, 2026, price HK$0.9000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Bio-heart Biological (2185)?
Balance-sheet figures for Shanghai Bio-heart Biological (as of Nov 10, 2026): return on equity −12.2%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 2185 from its 52-week high?
Shanghai Bio-heart Biological trades at HK$0.9000, about 88% below its 52-week high of HK$7.43 and at the low of HK$0.9000 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.9274 is for.
Which stocks are comparable to Shanghai Bio-heart Biological?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Bio-heart Biological stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.9000, calculated fair value HK$0.9274 (+3%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Shanghai Bio-heart Biological currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Bio-heart Biological (2185)?
The closing price on Nov 13, 2026 was HK$0.9000. Our estimate is HK$0.9274, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Bio-heart Biological right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Shanghai Bio-heart Biological

How large is the market capitalisation of Shanghai Bio-heart Biological (2185)?
The market capitalisation of Shanghai Bio-heart Biological is HK$222M (≈ $28.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Bio-heart Biological (2185)?
The price-to-sales ratio of Shanghai Bio-heart Biological is 6.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Shanghai Bio-heart Biological (2185)?
The return on equity (ROE) of Shanghai Bio-heart Biological is −12.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Bio-heart Biological (2185)?
On an EBIT basis the return on assets of Shanghai Bio-heart Biological is −20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Bio-heart Biological (2185)?
The operating margin of Shanghai Bio-heart Biological is −261% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Bio-heart Biological (2185)?
Revenue at Shanghai Bio-heart Biological is down 31.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Shanghai Bio-heart Biological (2185) generate?
The free cash flow of Shanghai Bio-heart Biological is −72.9M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Shanghai Bio-heart Biological (2185) hold?
Shanghai Bio-heart Biological holds more cash than debt, 79.6M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Shanghai Bio-heart Biological in the live analysis

One click puts Shanghai Bio-heart Biological on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.